Patents by Inventor Bruce A. Molitoris
Bruce A. Molitoris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140227189Abstract: A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.Type: ApplicationFiled: April 16, 2014Publication date: August 14, 2014Applicant: Indiana University Research and Technology CorporationInventors: Weiming YU, Bruce A. MOLITORIS, Ruben M. SANDOVAL
-
Publication number: 20140193343Abstract: The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV?TVPV.Type: ApplicationFiled: March 13, 2014Publication date: July 10, 2014Applicant: PHARMACOPHOTONICS, INC. D/B/A FAST DIAGNOSTICSInventors: Bruce A. Molitoris, Exing Wang, Roben M. Sandoval, JR.
-
Patent number: 8741263Abstract: A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.Type: GrantFiled: December 10, 2012Date of Patent: June 3, 2014Assignee: Indiana University Research and Technology CorporationInventors: Weiming Yu, Bruce A. Molitoris, Ruben M. Sandoval
-
Publication number: 20140140922Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: QUARK PHARMACEUTICALS, INC.Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Publication number: 20140050667Abstract: A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.Type: ApplicationFiled: October 24, 2013Publication date: February 20, 2014Applicant: PHARMACOPHOTONICS, INC. D/B/A FAST DIAGNOSTICSInventors: Exing Wang, Daniel Meier, Robert Bunch, Bruce Molitoris, Ruben Sandoval, Matthew Rubin
-
Patent number: 8637482Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: GrantFiled: June 7, 2010Date of Patent: January 28, 2014Assignee: Quark Pharmaceuticals, Inc.Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Patent number: 8591865Abstract: A method for measuring a glomerular filtration rate of a mammalian subject comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the vascular system of the mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the glomerular filtration rate.Type: GrantFiled: November 15, 2010Date of Patent: November 26, 2013Assignee: Pharmacophotonics, Inc.Inventors: Exing Wang, Daniel Meier, Robert Bunch, Bruce Molitoris, Ruben Sandoval, Matthew Rubin, Erinn Sheridan
-
Patent number: 8329143Abstract: A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.Type: GrantFiled: April 18, 2006Date of Patent: December 11, 2012Assignee: Indiana University Research and Technology CorporationInventors: Weiming Yu, Bruce A. Molitoris, Ruben M. Sandoval, Jr.
-
Publication number: 20120276014Abstract: The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV?TVPV.Type: ApplicationFiled: April 29, 2010Publication date: November 1, 2012Applicant: PHARMACOPHOTONICS, INC.Inventors: Bruce A. Molitoris, Exing Wang, Ruben M. Sandoval
-
Publication number: 20120157398Abstract: Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.Type: ApplicationFiled: December 8, 2011Publication date: June 21, 2012Inventors: Bruce A. Molitoris, David M. Bedwell, Ruben M. Sandoval
-
Publication number: 20120141378Abstract: The present invention relates to methods for treating chronic kidney disease (CKD) including methods for preventing or delaying onset of CKD and methods for preventing exacerbation and progression of CKD. In particular embodiments, the invention provides methods for treating a subject at risk of developing CKD comprising administering to the subject a composition comprising a) a therapeutically effective amount of at least one oligonucleotide compound which inhibits the expression of a human target gene associated with the kidney disease; and b) a pharmaceutically acceptable excipient or carrier, or mixtures thereof, thereby reducing the risk of CKD in the subject.Type: ApplicationFiled: June 7, 2010Publication date: June 7, 2012Inventors: Elena Feinstein, Svetlana Adamsky, Shai Erlich, Bruce Molitoris
-
Patent number: 8076298Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.Type: GrantFiled: December 10, 2007Date of Patent: December 13, 2011Assignees: Eli Lilly and Company, Indiana University Research and Technology CorporationInventors: Brian William Grinnell, Bryan Edward Jones, Bruce A. Molitoris
-
Publication number: 20110201940Abstract: A method for measuring a glomerular filtration rate of a mammalian subject comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the vascular system of the mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the glomerular filtration rate.Type: ApplicationFiled: November 15, 2010Publication date: August 18, 2011Inventors: Exing Wang, Daniel Meier, Robert Bunch, Bruce Molitoris, Ruben Sandoval, Matthew Rubin, Erinn Sheridan
-
Publication number: 20100204171Abstract: Various aspects related to the preparation of congeners of the aminoglycosides gentamicin such as the congener C2 and using this compound or derivatives thereof and pharmaceutically active salts to treat diseases that involve genetic mutations which introduce a missense or premature stop codon into a gene. Still other aspects include treating human or animal patients with the gentamicin congener C2 and derivatives and pharmaceutical salt thereof to overcome, or to at least mitigate, the symptoms of disease and disorders such as some forms of Becker's or Duchenne muscular dystrophy, Hurler's Syndrome and Cystic Fibrosis that have as their etiology the presence of a premature stop codon in a gene whose proper expression is necessary for good health.Type: ApplicationFiled: May 28, 2009Publication date: August 12, 2010Inventors: Bruce A. Molitoris, David M. Bedwell, Ruben M. Sandoval
-
Publication number: 20100087368Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.Type: ApplicationFiled: December 10, 2007Publication date: April 8, 2010Applicant: ELI LILLY AND COMPANYInventors: Brian William Grinnell, Bryan Edward Jones, Bruce A. Molitoris
-
Publication number: 20090285761Abstract: A method for measuring a glomerular filtration rate in a mammalian kidney comprises a source of reporter and marker fluorescent molecules. The fluorescent molecules are introduced into the blood stream of a mammalian subject. Over a period of time, a measurement of the intensities of the reporter and marker fluorescent molecules is taken. A ratio is calculated to determine the health of the subject's kidney. This method measures volume of plasma distribution based on a fluorescence of a marker molecule relative to a fluorescence of a reporter molecule.Type: ApplicationFiled: April 17, 2009Publication date: November 19, 2009Applicant: PHARMACOPHOTONICS, LLC D/B/A FAST DIAGNOSTICSInventors: Exing Wang, Daniel Meier, Robert Bunch, Bruce Molitoris, Ruben Sandoval, Matthew Rubin
-
Publication number: 20090234205Abstract: A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface.Type: ApplicationFiled: April 18, 2006Publication date: September 17, 2009Inventors: Weiming Yu, Bruce A. Molitoris, Ruben M. Sandoval, JR.
-
Publication number: 20080255047Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin. In conjunction with standard of care, soluble thrombomodulin will reduce tissue injury and subsequent morbidity and mortality.Type: ApplicationFiled: October 12, 2006Publication date: October 16, 2008Inventors: Brian William Grinnell, Thurman Dwight McKinney, Bruce A. Molitoris